chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Quarter sized rash at injection site; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 19Apr2021 at 12:15 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine sodium (SYNTHROID) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 26Mar2021 at 12:15 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 10:00, the patient had a quarter sized rash at injection site. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measure was not taken as a result of the events. The clinical outcome of the event quarter sized rash at injection site was resolved on 21Apr2021.   No follow-up attempts are needed. No further information is expected.
patient received a vaccine on wednesday, march, 31, 2021.  during the administration process, rph explained all side effects and what to expect from the covid 19 vaccine. patient bled a little after receiving the vaccine, so rph cleaned and wiped up spot. she waited 15 minutes, and then left.  on friday, april 2, 2021, patient told club manager, that she didn't feel good and she went to urgent care.  urgent care didn't give her any medications and told her to take an antihistamine and sent her home. urgent care told patient to check with pharmacy that gave her the vaccine.  saturday came, april 3, 2021 and she came to talk to rph. she said her arm is sore, she had headaches, nausea, and didn't feel good in general. Pharmacist told her these are common side effects of the vaccine patient told to take motrin or tylenol if she continues to not feel good.  she told pharmacist she will go to pcp on monday if she doesn't feel better.  On tuesday, 04/06, patient said all of of her symptoms and side effects have resolved and the only side effect she still has is a sore arm.  she didn't go to pcp since she felt better.
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash around the injection), VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE ERYTHEMA (red circle) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination. No medical history was provided by the reporter. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for Clotting disorder. On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (rash around the injection), VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE ERYTHEMA (red circle). The patient was treated with CAMPHOR, DIPHENHYDRAMINE HYDROCHLORIDE, ZINC OXIDE (BENADRYL [CAMPHOR;DIPHENHYDRAMINE HYDROCHLORIDE;ZINC OXIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (rash around the injection), VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE ERYTHEMA (red circle) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
PSORIASIS / LOOKED LIKE SOMEONE SCRATCHED / WREATH AROUND THE BACK OF THE HEAD; This spontaneous report received from a patient concerned a 57 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had no previous medical history. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1821288, expiry: UNKNOWN) dose was not reported, administered on 18-JUL-2021 for prophylactic vaccination. No concomitant medications were reported. On JUL-2021, the patient experienced psoriasis / looked like someone scratched / wreath around the back of the head. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from psoriasis / looked like someone scratched / wreath around the back of the head. This report was non-serious.
Patient developed a dermatomal rash on his upper right back, neck, and shoulder. Rash is vesicular. Follow-up in clinic on 09.25.2015 confirmed the rash and exam revealed no other adverse reactions.
BODY ACHES; FEVER; EXHAUSTED; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018, and expiry: UNKNOWN) dose was not reported, administered on 11-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 18-MAR-2021, Laboratory data included: COVID-19 virus test (NR: not provided) Negative. On an unspecified date, the subject experienced body aches, fever, and exhausted. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever, body aches and exhausted was not reported. This report was non-serious.
This case was reported by a pharmacist and describes the occurrence of autoimmune hepatitis in an adult female patient who received hepatitis B vaccine recombinant (Engerix B) for prophylaxis. The patient received injections of Engerix B on March 10, 2003 and May 02, 2003. At an unspecified time after the second dose, the patient travelled to visit family for three to four days. On the last day of the visit, the patient developed vomiting and diarrhea and "thought she had the flu". "A few days later", the patient became yellow. She was seen by a physician, who made a diagnosis of autoimmune hepatitis. The outcome of the event was unknown. Autoimmune hepatitis is considered to me medically serious. (OMIC)
Presents to ED after reaction to Covid vaccine. Patient states she received her injection and was waiting up between 5 to 10 minutes after the injection. She acutely felt tingling in her throat short of breath and describes "wave of purple halos around lights". She had 2 significant episodes of this and was provided epinephrine injection at the vaccine facility and sent to ED for further evaluation. She is still feeling extremely shaky and jittery and is complaining of mild dyspnea. Patient provided Benadryl, fluids, Pepcid. Chest x-ray is unremarkable and EKG is sinus tachycardia. Patient observed for several hours without recurrence or worsening of symptoms. Patient stable for discharge home and close follow-up with PCP in the next 1 to 2 days. Patient discharged with steroids, Benadryl and EpiPen and counseled regarding biphasic reaction precautions. Treating physician was (withheld).
Information was received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received concerning the patient's past medical history, concurrent conditions, or concomitant medication. During 2015, the patient was vaccinated at a physician office with ZOSTAVAX (lot number, dosage, and route of administration not provided), as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX vaccine did not prevent shingles as intended. On or about 01-MAY-2016, the patient was treated and diagnosed with herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Headache, Myalgia NA Narrative: Employee has h/o migraine headache that she uses replax intermittently for more than 10 years. Employee claimed after she got the covid vaccine , she developed light head. Then She started having headache that got worse progressively. She stated that she took her routine medication with no relief. She took more doses than usual, in addition to Tylenol. Stated that headache continued till the following day, that she called off work, 12/30/20. She said she slept the whole day yesterday and headache had subsided. She denied dizziness, nausea and vomiting.
flagellate rash anterior/posterior trunk. papular rash left leg, papular rash both arms, rash both palms.
Tinnitus. My ears have been ringing non-stop since September 2022. It got worse after contracting Covid-19 in November 2022.
"dribbled some of the vaccine onto chin"; No adveser effects; This spontaneous report has been received from a nurse referring to a patient of unknown age. Information regarding the patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications was not reported.      On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent(ROTATEQ), oral (indication, strength, dose, frequency, route of administration, lot number and expiration date were not provided) for prophylaxis. During administration "dribbled some of the vaccine onto chin". No adverse effects were reported.
Information has been received from a physician concerning a patient who was vaccinated with the second dose of Gardasil vaccine (date, route, and dose information was unavailable for both the first and second dose of Gardasil vaccine). Subsequently, the patient experienced an immune response reaction. The reporter felt that immune response reaction were not related to therapy with Gardasil vaccine. Additional information has been requested.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 25-FEB-2008, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) for routine adult health maintenance and the intended purpose of the long-term prevention of shingles and zoster-related injuries. The ZOSTAVAX did not prevent shingles and zoster-related injuries as intended. In 2015, the patient was treated by physicians for shingles and zoster related injuries. As a direct and proximate result of the ZOSTAVAX, and/or despite receiving ZOSTAVAX for long term prevention of shingles and zoster-related injuries, the patient suffered painful injuries and damages and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Soreness at injection site, fever (temp = 102 on day 2), syncope X 1
devel sl case of chicken pox # 20 water-filled some, other never coming to head, fever;
11jun90 pt vax 3rd hepta B. 14jun90 pt could no longer maintain therapeutic level of nortriptyline.  18jun90 pt ex diarrhea w/ gastrointestinal cramps.
sick; nausea; diarrhea; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP) for a Pfizer sponsored program.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for COVID-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MALAISE (non-serious), outcome "unknown", described as "sick"; NAUSEA (non-serious), outcome "unknown", described as "nausea"; DIARRHOEA (non-serious), outcome "unknown", described as "diarrhea".  Additional information: Reporter and his wife want to reschedule their 2nd dose which is due tomorrow the 18Mar2021 because his wife is sick. His wife had arthroscopic surgery and is experiencing nausea and diarrhea. The date of their 1st dose was not verified.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I received the vaccine on 09/23/2022 and I had to go to the emergency room. I have memory issues, finding simple words, unable to react normally, hyper upset, panic attacks, fear, anxiety, severe diarrhea. I was observed for overnight. Nothing was found and it was decided that I had an extreme reaction to the vaccine.
Patient reported tingling down her are approximately 5 minutes after the injection.  She reported muscle stiffness.  She was unable to lift her arm to get dressed.  Symptoms subsided but have now re-occurred.
exposure via skin contact; Inadvertent exposure to vaccine; rash; underdose; This case was reported by a consumer via call center representative and described the occurrence of injection site rash in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 3rd May 2019, the patient received the 1st dose of Shingrix. On 3rd May 2019, less than a day after receiving Shingrix, the patient experienced injection site rash and accidental underdose. On an unknown date, the patient experienced exposure via skin contact and inadvertent exposure to vaccine. On an unknown date, the outcome of the injection site rash, accidental underdose, exposure via skin contact and inadvertent exposure to vaccine were unknown.   It was unknown if the reporter considered the injection site rash to be related to Shingrix.  Additional details were provided as follows: The case was reported by patient's daughter. It was reported that the patient received Shingrix either on 3rd May 2019 or 4th May 2019 on an unknown arm. It was reported that a family member told her that the patient received a partial dose of Shingrix, and some of it ran down her arm, which led to accidental underdose, exposure via skin contact and inadvertent exposure to vaccine and she developed rash where the vaccine ran down her arm.  The patient did not consent to follow-up.  The reporter declined to provide the details of her mother's experience and did not know other details. This was the only information available and was documented.  The reporter was unsure if this case was reported to GSK previously.
Pt had headache, nausea and vomiting. Headache developed within 15-minutes of vaccine administration and vomiting occured at about 15-minutes from vaccine administration. Patient recovered with being in reclined position, rest, and cold pack to her head. Was offered water, which made her vomit again. Vitals were WNL. Pt recovered.
Skin became hot, burning, difficulty swallowing, difficulty breathing, anxiety, dizziness, light headed.  Took benadryl po 50 mg.  Was seen at ER. Received albuterol neb, steroids IV, and prevacid PO.  Sent home with po steroids and benadryl.  S/S improved after treatment.
06/07/2005 Client was given TD vaccine into left deltoid muscle by intramuscular route.  On 06/08/2005 patient called to complain of lymph node swelling in axillae of left arm.  06/10/2005 RS returned to office and no turned clients call.
Death Narrative: 83 y.o. male with pmh of heart failure admitted on 3/9 for shortness of breath and weight gain. Had Vfib arrest on 3/12 and was intubated/xfer to ICU. Continued to require increasing levels of pressors. He suffered VF arrest in the setting of metabolic, septic and cardiogenic shock. He had end stage heart failure and required 4 pressors. Was made CMO and passed away. Noted to have not received 2nd does of Moderna likely due to hospitalization at the time that the second dose would have been due. Patients history of adverse drug reactions included: lisinopril, dabigatran, and penicillin.
Information has been received from a medical assistant concerning a 23 year old female with no pertinent medical history who on approximately 02-FEB-2007 was vaccinated with a first dose of Gardasil. On 02-APR-2007, the patient was vaccinated, intramuscularly, with a second dose of Gardasil. Concomitant therapy included hormonal contraceptives (unspecified). On 02-APR-2007, within a few hours of the vaccination, the patient experienced shortness of breath and nausea. She called the physician's office and the physician prescribed Benadryl. There were no laboratory or diagnostic tests performed. The patient's outcome was unknown. Additional information has been requested.
Patient stated he did not feel good. Stated his chest felt tight. Patient was immediately taken to exam for evaluation by Dr.
slight sporadic blurriness of vision.; slight headache; Soreness at site of administration; full body aches; soreness at site of administration, full body aches; This is a spontaneous report received from a contactable consumer, the patient. A 49-year-old non-pregnant female the received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL3247), via an unspecified route of administration in the left arm on 16Mar2021 at 09:45(at the age of 49-years-old), as a second single dose for COVID-19 immunisation. No significant medical history included. The patient did not have any allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. Concomitant medications included vitamins D (MANUFACTURER UNKNOWN) and Vitamin B3 (MANUFACTURER UNKNOWN) for an unknown indication from an unspecified date and unknown if its ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received BNT162B2 (Lot number: EL3247), in the left arm on 23Feb2021 at 09:45AM (at the age of 49-years-old), as a first single dose for COVID-19 immunisation and experienced general but mild full body aches, Soreness and tenderness at the injection site. On 16Mar2021, the patient was experienced soreness at site of administration, full body aches, slight headache, slight sporadic blurriness of vision. The patient did not receive any treatment for all the events. The clinical outcome of vaccination site pain, general body pain, slight headache, slight sporadic blurriness of vision was recovering.   No follow-up attempts are needed. No further information is expected.
Itchy; Swelling at the injection site; Redness at the injection site; Mild pain and tenderness at the injection site; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PRURITUS (Itchy) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     Concomitant products included HYDROCHLOROTHIAZIDE, ATORVASTATIN, LORATADINE, UBIDECARENONE (QUNOL LIQUID COQ10), CALCIUM CARBONATE, COLECALCIFEROL (CALTRATE 600 + D), MULTI VITAMIN ONE A DAY, TRIAMCINOLONE ACETONIDE (NASACORT) and APOAEQUORIN, COLECALCIFEROL (PREVAGEN [APOAEQUORIN;COLECALCIFEROL]) for an unknown indication.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (Itchy). At the time of the report, VACCINATION SITE PRURITUS (Itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment for the events included diphenhydramine.
This spontaneous report as received from a pharmacist refers to a currently 78 years old female patient. The patient had no known allergies. The patient was vaccinated with 0.65 ml ZOSTAVAX (lot number was not provided) subcutaneous in left arm on 03-SEP-2012. No other co-suspects were reported. Concomitant medication included COUMADIN. Three days post vaccination. on 06-SEP-2012 the patient experienced injection site was red and hot to touch. Pharmacist stated since then, the reaction started to clear up, but now arm was pink in color that runs down her arm to her left elbow, and is warm to touch. The outcome was unknown at the time of report. The patient had called pharmacy to seek medical attention. Additional information is not expected.
101 fever x 24 hours 3-5-16 headache, body aches.
Headache, UrticariaPruritus, Light sensitivity. Fatigue. Bounding headache. Injection site redness - silver dollar sized. Tender and warm. Narrative:  Evaluated and cleared by Occ. Health on 12/30/20/ Historically, patient tested COVID positive in July. 1/6/21-Patient sent to Occ. Health today again. Redness increasing with induration. Hot to touch. Reports extreme itching.
Third day after first vaccine noted pain in soft palate and obserrved redness and central white ulceration. It improved over next week only to reappear after second vaccine and in this case took 6 weeks to disappear. It was painful and verified by two dentists who saw lesion.  I also develop three days after second vaccine, pain in right calf region and numbness in my right foot involving lateral toes and heel region. the pain disappeared within hours but the numbness has remained, now 6 weeks ater though is less than initially,   After both the first and second vaccinations, I had hemorrhagic sinusitis that lasted at least two weeks with significant drainage resulting in cough.   I had two negative Covid tests after first vaccine to confirm this was vaccine related and I had not contracted Covid.
Starting 11/10/2021 - fatigue and general body aches. Starting 11/13/2021 - beginning signs of rash Starting 11/15/2021 - widespread rash, obvious signs of Shingles
No additional adverse effects were reported.; A patient received a dose of a vaccine that had been improperly stored; This spontaneous report has been received from a physician referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history, drug/allergy reactions, and concomitant therapies were not reported.  On 20-APR-2020 the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX), 0.5 milliliter, subcutaneous for prophylaxis (lot number S032353, expiration date 14-OCT-2021). Additionally sterile diluent (MERCK STERILE DILUENT) was reported.  The administered dose of the vaccine experienced a temperature excursion between -9 degrees Celsius to 8 degrees Celsius for 3 hours/59 minutes, as recorded by a data logger. There was no previous temperature excursion reported.  No adverse event was informed by the reporter.